<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04585750</url>
  </required_header>
  <id_info>
    <org_study_id>PMV-586-101</org_study_id>
    <nct_id>NCT04585750</nct_id>
  </id_info>
  <brief_title>The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation</brief_title>
  <official_title>A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PMV Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PMV Pharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety and tolerability of multiple dose levels of PC14586 in&#xD;
      participants with advanced solid tumors containing a p53 Y220C mutation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PC14586 is a first-in-class, oral, small molecule p53 reactivator that is selective for the&#xD;
      p53 Y220C mutation. The trial will be conducted in 2 parts: dose escalation (Phase 1) and&#xD;
      dose expansion (Phase 2).&#xD;
&#xD;
      The primary objective of Phase 1 is to establish the maximum tolerated dose / recommended&#xD;
      dose of PC14586 to treat participants with advanced solid tumors harboring a p53 Y220C&#xD;
      mutation. Secondary objectives of Phase 1 are to characterize the pharmacokinetic properties&#xD;
      of the investigational drug, its safety and tolerability, and to assess the overall response&#xD;
      rate (ORR).&#xD;
&#xD;
      The primary objective of Phase 2 is to assess the ORR in participants with advanced solid&#xD;
      tumors harboring a p53 Y220C mutation as determined by blinded independent central review.&#xD;
      Secondary objectives of Phase 2 include the safety, pharmacokinetic properties, and efficacy&#xD;
      of PC14586 at the recommended dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 29, 2020</start_date>
  <completion_date type="Anticipated">December 15, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>During Phase 1 (Dose Escalation), participants will be assigned a dose level using an accelerated titration design in the initial dose cohorts, followed by a modified toxicity probability interval (mTPI) design in subsequent dose cohorts. A Recommended Phase 2 Dose (RP2D) will be selected at the end of Phase 1 and in Phase 2 (Dose Expansion) the RP2D will be assigned to all participants.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the number and type of adverse events to characterize the safety of PC14586</measure>
    <time_frame>48 months for study (Phase 1 and 2)</time_frame>
    <description>Number of participants with treatment related adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Establish the maximum tolerated dose (MTD) (Phase 1)</measure>
    <time_frame>The first 21 days of treatment (Cycle 1) per patient</time_frame>
    <description>Incidence of dose limiting toxicities (DLTs) during the first 21-day cycle of PC14586</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Establish the Recommended Phase 2 Dose (RP2D) (Phase 1)</measure>
    <time_frame>20 months for study (end of Phase 1)</time_frame>
    <description>RP2D will be determined using available safety and pharmacokinetics and pharmacodynamics data</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rate assessment to evaluate the clinical activity / efficacy of PC14586 (Phase 2)</measure>
    <time_frame>48 months for study (Phase 1 and 2)</time_frame>
    <description>Overall response rate in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1 as assessed by independent review</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood plasma assessment to characterize the pharmacokinetics (PK) of PC14586 and metabolites (Phase 1 and 2)</measure>
    <time_frame>Approximately 12 months per patient (48 months for study)</time_frame>
    <description>Blood plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate assessment to assess clinical activity / efficacy of PC14586 (Phase 1)</measure>
    <time_frame>20 months for study (end of Phase 1)</time_frame>
    <description>Overall response rate in accordance with Response Evaluation Criteria in Solid Tumors</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <condition>Advanced Malignant Neoplasm</condition>
  <condition>Metastatic Cancer</condition>
  <condition>Metastatic Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Phase 1 Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple dose levels of PC14586 will be evaluated in an escalating manner, to determine the maximum tolerated dose and to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of PC14586 to recommend a Phase 2 dose (RP2D).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Dose Expansion, Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Additional (expansion of) participants will enroll at the RP2D of PC14586 for continued evaluation. Cohort A participants will have advanced solid tumors harboring a p53 Y220C mutation who meet all eligibility criteria and have measureable disease per RECIST 1.1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Dose Expansion, Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Additional (expansion of) participants will enroll at the RP2D of PC14586 for continued evaluation. Cohort B participants will have advanced solid tumors harboring a p53 Y220C mutation who do not meet all eligibility criteria (e.g. have a primary central nervous system (CNS) tumor) and do not have measurable disease per RECIST 1.1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PC14586</intervention_name>
    <description>PC14586 is a first-in-class, oral, small molecule p53 reactivator that is selective for the p53 Y220C mutation, being developed for the treatment of patients with advanced solid tumors harboring a p53 Y220C mutation. PC14586 will be administered orally on a continuous regimen.</description>
    <arm_group_label>Phase 1 Dose Escalation</arm_group_label>
    <arm_group_label>Phase 2 Dose Expansion, Cohort A</arm_group_label>
    <arm_group_label>Phase 2 Dose Expansion, Cohort B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 18 years of age or 12 to 17 years of age after adequate adult safety data&#xD;
             become available&#xD;
&#xD;
          -  Advanced solid malignancy with a p53 Y220C mutation&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) status of 0 or 1&#xD;
&#xD;
          -  Previously treated with one or more lines of anticancer therapy and progressive&#xD;
             disease&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Anti-cancer therapy within 21 days (or 5 half-lives) of receiving the study drug&#xD;
&#xD;
          -  Radiotherapy within 28 days of receiving the study drug&#xD;
&#xD;
          -  Primary CNS tumor (Phase 1, Phase 2 Cohort A)&#xD;
&#xD;
          -  History of leptomeningeal disease or spinal cord compression&#xD;
&#xD;
          -  Brain metastases, unless neurologically stable and do not require steroids to treat&#xD;
             associated neurological symptom&#xD;
&#xD;
          -  Stroke or transient ischemic attack within 6 months prior to screening&#xD;
&#xD;
          -  Heart conditions such as unstable angina, uncontrolled hypertension, a heart attack&#xD;
             within 6 months prior to screening, congestive heart failure, prolongation of QT&#xD;
             interval, or other rhythm abnormalities&#xD;
&#xD;
          -  Strong CYP3A4 inhibitors or inducers, medications with a known risk of QT/QTc&#xD;
             prolongation, or proton pump inhibitors&#xD;
&#xD;
          -  History of gastrointestinal (GI) disease that may interfere with absorption of study&#xD;
             drug or patients unable to take oral medication&#xD;
&#xD;
          -  History of prior organ transplant&#xD;
&#xD;
          -  Known, active malignancy, except for treated cervical intraepithelial neoplasia, or&#xD;
             non-melanoma skin cancer&#xD;
&#xD;
          -  Known, active uncontrolled Hepatitis B, Hepatitis C, or human immunodeficiency virus&#xD;
             infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>PMV Pharma Clinical Study Information Center</last_name>
    <phone>(609) 235-4038</phone>
    <email>clinicaltrials@pmvpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>USC Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony El-Khoueiry, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hoag Memorial Hospital Presbyterian</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony El-Khoueiry, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Munster, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aparna Parikh, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geoffrey Shapiro, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison Schram, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Heath &amp; Science University (OHSU)</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shivaani Kummar, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon and HCA Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Johnson, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>New Experimental Therapeutics - NEXT Oncology</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Tolcher, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Escaterina Dumbrava, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>New Experimental Therapeutics of San Antonio - NEXT Oncology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Tolcher, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Washington, Seattle Cancer Care Alliance (SCCA)</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Thompson, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 1, 2020</study_first_submitted>
  <study_first_submitted_qc>October 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PC14586</keyword>
  <keyword>p53</keyword>
  <keyword>Y220C</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Phase 1/2</keyword>
  <keyword>PMV</keyword>
  <keyword>PMV Pharma</keyword>
  <keyword>p53 mutation</keyword>
  <keyword>TP53</keyword>
  <keyword>TP53 mutation</keyword>
  <keyword>p53 mutant</keyword>
  <keyword>p53 reactivator</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

